Key Highlights

  • Enlivex Therapeutics (NASDAQ:ENLV) shows a 20.79% decline, a quote of USD 1.41 and an RSI of 11.69 on the screen used here, with Volume 2.71 times normal. All are unverified screener figures.
  • Published market data on November 4, 2026 showed USD 1.43, a Market Capitalisation of about USD 2.19 million and 1.53 million shares. The 52-week range of USD 1.40 to USD 434.40 reflects reverse splits.
  • The company reported a Nasdaq delisting notice on October 27, 2026 and said it intends to appeal. A reverse share split took effect the same day, and the reported ratio varied across listings.
  • On November 2, 2026 the company reported favorable 12-month topline data from a Phase I/IIa Allocetra trial, and on October 28, 2026 it said 135 patients were randomized in a Phase 2b knee osteoarthritis trial.

What Happened

Enlivex Therapeutics (NASDAQ:ENLV) is an Israel-based clinical-stage company developing cell-based immunotherapies. Its lead candidate, Allocetra-OTS, is an off-the-shelf cell therapy made from apoptotic cells. Company news flow in the final week of October and early November 2026 was crowded. A Nasdaq delisting notice and an appeal intention were reported on October 27, 2026. Trial updates followed on October 28 and November 2, 2026. The screen shows a one-day fall of 20.79%, and no single announcement was confirmed as the cause, so none is assigned here. The company also said 135 patients had been randomized in a Phase 2b study, which is a trial design step and not a data readout.

How Reverse Splits and Notices Work

A reverse split merges shares into fewer, higher-priced ones, lifting the quoted price without changing the value of a holding. Companies use it to meet minimum bid rules. When a stock then falls after a split, the RSI, which averages gains and losses over 14 sessions on a 0 to 100 scale, can collapse toward 11.69 even though the bounce in price was mechanical. A delisting notice means shares could trade over the counter if an appeal fails. The grounds of the notice were not confirmed. Market data also lists a consensus target near USD 4,800, which looks like a split-related data error. Because the price is so low, a trade of a few thousand shares can shift the quote noticeably, which exaggerates the RSI.

Risks and What to Watch

With a market capitalisation near USD 2.19 million, a small number of trades can move the price, spreads can be wide and quoted moves can reverse. Clinical-stage biotechs depend on trial data and financing, and the company cash position was not found. Favorable topline data from an early-stage study is not proof of efficacy in a larger Phase 2b trial. Watch the Nasdaq appeal outcome, any new financing and the Phase 2b timeline. Split ratios were reported inconsistently, one-for-16 and one-for-15, so check the company filings. Retail holders should also check how many warrants or convertible instruments are outstanding, because they can add shares quickly.

Where Things Stand

Enlivex is oversold on the screen reading because a delisting notice, a reverse split and heavy price swings arrived together, not because of a confirmed single trigger. The favorable November 2, 2026 topline data and the Phase 2b enrollment show the science continuing, but the share price is being driven by listing risk and a market capitalisation near USD 2.19 million. A low RSI of 11.69 shows selling pressure and says nothing about the appeal. The next dated item is the Nasdaq appeal process, with no hearing date confirmed.